Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasda ...